To determine the interactive effect between 17-AAG treatment and CP on CML CD34+ cells, Chou-Talalay analysis was performed as previously described [40]. The fixed ratios of 17-AAG and CP and mutually exclusive equations were used to determine the Combination Index (CI) according to the method of Chou-Talalay using Compusyn Software (Combosyn, Inc., NJ). Briefly, the combined dose-response curves were fitted to Chou-Talalay lines, which are derived from the law of mass action and described by the equation: log(f a /f u ) = m log(D) − m log(Dm), in which f a is the fraction affected, f u is the fraction unaffected, D is the dose, D m is the median-effect dose, and m is the coefficient signifying the shape of the dose-response curve. The CI values were calculated using the equation: CI = (D1/Dx1) + (D2/Dx2) + (D1) (D2)/[(Dx1) (Dx2)], where Dx1 and Dx2 are the 17-AAG and CP doses, respectively, which are required to achieve a particular f a , and D1 and D2 are the doses of the 2 treatments (combined treatment) required for achieving the same f a . CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. 
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SUPPLEMENTARY MATERIAL
Chou-Talalay analysis
To determine the interactive effect between 17-AAG treatment and CP on CML CD34+ cells, Chou-Talalay analysis was performed as previously described [40] . The fixed ratios of 17-AAG and CP and mutually exclusive equations were used to determine the Combination Index (CI) according to the method of Chou-Talalay using Compusyn Software (Combosyn, Inc., NJ). Briefly, the combined dose-response curves were fitted to Chou-Talalay lines, which are derived from the law of mass action and described by the equation: log(f a /f u ) = m log(D) − m log(Dm), in which f a is the fraction affected, f u is the fraction unaffected, D is the dose, D m is the median-effect dose, and m is the coefficient signifying the shape of the dose-response curve. The CI values were calculated using the equation:
, where Dx1 and Dx2 are the 17-AAG and CP doses, respectively, which are required to achieve a particular f a , and D1 and D2 are the doses of the 2 treatments (combined treatment) required for achieving the same f a . CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic interactions, respectively. Figure 3B using Compusyn software. CI values of <1 occurred at a wide range of inhibition levels, indicating synergy produced by the combination. E-F. Median-effect plot and fraction affected-CI plot of 17-AAG+CP were constructed by computer analysis of the data in Figure 3C using Compusyn software. CI values of <1 occurred at a wide range of inhibition levels, indicating synergy produced by the combination. Supplementary Figure 3: A. The proliferation of K562 or K562/G01 cells in the presence of increasing concentrations of imatinib (0-32 000 nM). B. and E. Median-effect plot and fraction affected-CI plot of 17-AAG 3 h→CP 48 h were constructed by computer analysis of the data in Figure S3B using Compusyn software. CI values of <1 occurred at a wide range of inhibition levels, indicating synergy produced by the combination. C. and F. Median-effect plot and fraction affected-CI plot of CP 3 h→17-AAG 48 h were constructed by computer analysis of the data in Figure S3C using Compusyn software. CI values of <1 occurred at a wide range of inhibition levels, indicating synergy produced by the combination. D. and G. Median-effect plot and fraction affected-CI plot of 17-AAG+CP were constructed by computer analysis of the data in Figure S3D using Compusyn software. CI values of <1 occurred at a wide range of inhibition levels, indicating synergy produced by the combination.
